PubMed HealthSearch

PubMed · 9238356

Hormone replacement therapy.

Abstract

More than 40 million women in the United States are now going through or are past menopause. Another 3.5 million or more will reach midlife in the next decade. As their life expectancy increases (mean life expectancy of women is now approximately 84 years), so does the need for therapeutic regimens related to reproductive function and aging in woman. Few medical treatments available to menopausal and postmenopausal women have as much potential benefit as well as possible health risks as hormone replacement therapy (HRT). Despite the increasing amount of scientific data available regarding the benefits of HRT, a degree of uncertainty still remains, both in the minds of some women, and with some health professionals, regarding the risks associated with long-term therapy. Even though the literature is voluminous, contradictory, and unclear, health providers must be able to keep abreast of current knowledge about the benefits, risks, and unknowns of these drugs. The purpose of this article is to provide a review and an update on the types of hormones available for HRT, their pharmacology and pharmacokinetics, and their risks, benefits, and contraindications. Newer products, specially compounded formulas, new regimens, and new modes of delivery that offer women alternatives and allow care to be individualized are described. In addition, some of the ongoing management dilemmas that practitioners face with the woman who chooses HRT are presented with practical solutions and suggestions.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Scharbo-Dehaan. 1996. Hormone replacement therapy.. https://doi.org/10.1097/00006205-199612001-00001

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Heart transplants in infants: an estimate of need and restrictions].

The need for cardiac transplantation in children in the Netherlands can be estimated at 5-14 per year, including 1-3 in newborns. This treatment can only be successful in close cooperation with an existing programme for adult cardiac transplantation and in a centre where the surgery for congenital heart disease is performed to its complete extent. Heart transplantation should not be the primary treatment for hypoplastic left heart syndrome as the Norwood operation constitutes a good alternative. Donor shortage is a problem for children also. In the treatment of endstage heart disease in newborns, owing to ethical dilemmas, surgical treatment is not a matter of course.

Contraindications